Switching to Long-Acting Injectable Risperidone is Beneficial with Regard to Clinical Outcomes, Regardless of Previous Conventional Medication in Patients with Schizophrenia

Abstract

Introduction: Using an atypical long-acting antipsychotic may improve patient outcome by offering the good efficacy and tolerability of an atypical antipsychotic with improved compliance through depot administration.

Methods: This subanalysis of an international, 6-month, open-label trial of risperidone long-acting injectable (RLAI) focused on non-acute schizophrenic adult patients switching from oral or depot conventional antipsychotic. Efficacy assessments included Positive and Negative Syndrome Scale (PANSS), Global Assessment of Functioning (GAF), quality of life, treatment satisfaction, hospitalization rates, and treatment-emergent adverse events (TEAEs).

Results: Over 70% of patients switching from oral (n=100) or depot (n=565) conventional medication completed treatment. Improvements were observed for PANSS total and subscale scores, GAF, quality of life, treatment satisfaction and hospitalization. Overall RLAI was well tolerated. TEAEs occurring in >5% were: anxiety (11.0%), insomnia (9.0%), weight increase (6.0%) for patients switching from oral, and weight increase (6.0%) and disease exacerbation (5.3%) for patients switching from depot medication.

Conclusion: Patients with schizophrenia, unsatisfactorily treated with oral or depot conventional antipsychotics, showed improvement in symptom control, tolerability, and patient satisfaction after switching to RLAI.

References

• 1 American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity . Consensus development conference on antipsychotic drugs and obesity and diabetes.  Diabetes Care. 2004;  27 596-601
• 2 American Psychiatric Association .Diagnostic and Statistical Manual of Mental Disorders. 4th edition Washington, DC: American Psychiatric Association 1994
• 3 Bai YM, Chen TT, Wu B, Hung CH, Lin WK, Hu TM. et al . A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study.  Pharmacopsychiatry. 2006;  39 135-141
• 4 Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS).  Schizo Res. 2005;  76 247-265
• 5 Diaz E, Neuse E, Sullivan MC, Pearsall HR, Woods SW. Adherence to conventional and atypical antipsychotics after hospital discharge.  J Clin Psychiatry. 2004;  65:3 354-360
• 6 Dossenbach MK, Beuzen J, Avon M, Belmaker RH, Elizur A, Mark M. et al . The effectivenss of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine.  Clin Ther. 2000;  22 1021-1034
• 7 Essock SM, Covell NH, Davis SM, Scott Stroup T, Rosenheck RA, Lieberman JA. Effectiveness of switching antipsychotic medications.  Am J Psychiatry. 2006;  163 2090-2095
• 8 Godleski LS, Goldsmith J, Vieweg V, Zettwoch NC, Stikovac DM, Lewis SJ. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia.  J Clin Psychiatry. 2003;  64 119-122
• 9 Han C, Lee BH, Kim YK, Lee HJ, Kim SH, Kim L. et al . Satisfaction of patients and caregivers with long-acting injectable risperidone and oral atypical antipsychotics.  Prim Care Community Psychiatry. 2005;  10 119-124
• 10 Hugenholtz GK, Heerdink ER, Meijer WE, Stolker JJ, Egberts AG, Nolen WA. Reasons for switching between antipsychotics in daily clinical practice.  Pharmacopsychiatry. 2005;  38 122-124
• 11 Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.  Am J Psychiatry. 2003;  160 1125-1132
• 12 Kane JM, Meltzer HY, Carson WH, McQuade RD, Marcus RN, Sanchez R. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine.  J Clin Psychiatry. 2007;  68 213-223
• 13 Lasser RA, Bossie CA, Gharabawi GM, Turner M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone.  Eur Psychiatry. 2004;  19 219-225
• 14 Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo.  A meta-analysis of randomized controlled trials. Schizophr Res. 1999;  35 51-68
• 15 Lin CH, Lin SC, Chen MC, Wang SY. Comparison of time to rehospitalization among schizophrenic patients discharged on typical antipsychotics, clozapine or risperidone.  J Chim Med Assoc. 2006;  69 264-269
• 16 Makela EH, Cutlip WD, Stevenson JM, Weimer JM, Abdallah ES. et al . Brnaded versus generic clozaopine for treatment of schizophrenia.  Ann Pharmacother. 2003;  37 350-353
• 17 Möller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E. StoRMi Study Group . Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies.  Int Clin Psychopharmacol. 2005;  20 121-130
• 18 Möller HJ. Antipsychotic agents. Gradually improving treatment from the traditional oral neuroleptics to the first atypical depot.  Eur Psychiatry. 2005;  20 379-385
• 19 Osterberg L, Blaschke T. Adherence to medication.  N Engl J Med. 2005;  353 487-497
• 20 Patel NC, Dorson PG, Edwards N, Mendelson S, Crismon ML. One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics.  Psychiatric Serv. 2002;  53 891-893
• 21 Perkins DO. Predictors of noncompliance in patients with schizophrenia.  J Clin Psychiatry. 2002;  63 1121-1128
• 22 Simpson GM, Mahmoud RA, Lasser RA, Kujawa M, Bossie CA, Turkoz I. et al . A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.  J Clin Psychiatry. 2006;  67 1194-1203
• 23 Os J van, Bossie CA, Lasser RA. Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone.  Int Clin Psychopharmacol. 2004;  19 229-232
• 24 Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life.  Schizophr Res. 2000;  43 135-145
• 25 Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.  J Clin Psychiatry. 2003;  64 580-588

Correspondence